Home / Combinations / CJC-1295 + Ipamorelin
CombinationMuscle GrowthFat LossRecoveryAnti-AgingEmerging evidence
CJC-1295 + Ipamorelin
GH Optimization
A foundational growth hormone secretagogue stack pairing a GHRH analogue (CJC-1295) with a selective GH secretagogue (Ipamorelin). CJC-1295 amplifies GH output by extending GHRH signal duration, while Ipamorelin triggers additional GH pulses through the ghrelin receptor with minimal cortisol or prolactin elevation. Together they produce synergistic, more physiologically natural GH release compared to either peptide alone.
Stack components
CJC-1295 (without DAC)Compound 01
IpamorelinCompound 02
2
Compounds
2
Sources on file
281
Providers carry all
Mechanism
What each compound is researched for on its own. Nothing here describes an interaction between them.
Compound 01
CJC-1295 (without DAC)
Acts as the long-acting GHRH analogue backbone of the stack, extending natural GH pulse duration and amplitude through its DAC modification. Its sustained activity makes it the primary driver of elevated GH output across the dosing window.
Compound 02
Ipamorelin
A highly selective ghrelin receptor agonist that triggers additional GH pulses with negligible cortisol or prolactin co-stimulation, making it the cleanest available complement to a GHRH analogue. It synergises with CJC-1295 by activating GH release through an entirely distinct receptor pathway.
Composition
2 compounds · 4 research areas
Stated as recorded. This page describes each compound separately and makes no claim that they act together.
Safety notes
Both peptides are unapproved research compounds that stimulate endogenous growth hormone release. Contraindicated in individuals with active or suspected hormone-sensitive malignancies. Potential side effects include water retention, joint discomfort, and changes in insulin sensitivity consistent with elevated GH. Not for use during pregnancy or breastfeeding.
Author-written. Not derived from any compound field, and not covered by the profile-integrity audit that gates the peptide pages.
Research references2 sources
Moderate
Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults
J Clin Endocrinol Metab 2006
Moderate
Ipamorelin, the first selective growth hormone secretagogue
Eur J Endocrinol 1998
Related combinations3 share an area
Educational use only
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 19 Apr 2026.
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 19 Apr 2026.